(recap-dated July 29, 2011) Gynecologic Cancers Update from the 2011 Annual Oncology Meeting « OncoFacts

Gynecologic Cancers Update from the 2011 Annual Oncology Meeting

Reviewed by Bradley Monk, MD, FACS, FACOG

Daily Clinical Updates from the Annual Oncology Meeting in Chicago | prIME Oncology slides/interviews - Oza/Monk

Expert Interviews  Downloadable slides Release Date June 7, 2011	Expiration Date June 7, 2012
Faculty
Melanoma: Antoni Ribas, MD UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States	Ovarian Cancer: Amit Oza, MD Princess Margaret Hospital Toronto, Ontario, Canada	Genitourinary Malignancies: Dean Bajorin, MD Memorial Sloan-Kettering Cancer Center New York, New York, United States
Vernon Sondak, MD H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States	Bradley Monk, MD Creighton University School of Medicine at St Joseph's Hospital and Medical Center Phoenix, Arizona, United States

ELC : Imedex e-learning center March 8th, 2011 video (30 min) interviews from SGO

Note: requires password/registration to view videos (free), risk factors, hereditary, KRAS mutation/variant (in many other cancers as well), MiRnA, ICON7 (Avastin).....    

Featured Activity:

	You must be a registered Imedex.com member to access this. Please enter your email address and password. Email Password Remember me Don't have an account? Forgot your password?

Best of the Day: 2011 Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer

Dr Bradley Monk interviews 6 nationally recognized experts in GYN oncology about their interpretations of clinically relevant data presented at the annual meeting. Drs Deborah Armstrong, Barbara Goff, Tom Herzog, Warner Huh, Robert Coleman, and Robert Burger comprise the esteemed faculty.

Gyn Clinical Spotlights | slides/interviews: Dr's Fleming, Monk, Birrer

7 JUNE 2010
		These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release: #LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States. View the Primary Expert Analysis with Gini Fleming, MD, and Bradley Monk, MD, and access downloadable slides View the Supplemental Perspectives and Discussion with Bradley Monk, MD, and Michael Birrer, MD, PhD, and access downloadable slides

repost: abstract: (Yondelis) Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. BJ Monk et al

Note: Reposted from June 9th to coincide with Editorial from JCO; multinational study plus: JCO link

Gyn Clinical Spotlights | prIME Oncology

7 JUNE 2010


These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release:

#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study

The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States

The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States.

View the expert analysis with Gini Fleming, MD, and Bradley Monk, MD
View the expert analysis with Bradley Monk, MD, and Michael Birrer, MD, PhD
View eNewsflash